CMyGuideline - CML patient data for building decision making tool to predict CVD risk

Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative disorder of the hematopoietic system, caused by the constitutively active BCR-ABL tyrosine kinase from the translocation that produces the Philadelphia chromosome. Patients usually are treated with different Tyrosine Kinase Inhibitor (TKI) in their chronic phases for several years. During the treatment, cardiovascular disease risk (CVD) is one of the most important factors for doctors and patients to consider when making the optimal treatment plan for patients.

CVD Predictive Model: We plan to build models in 3 steps by adding the possible risk factors. We start with the model by only looking at the general population. Then, we add factors for CML patients and see if they have higher/lower CVD risks compared to the general population. Lastly, we add treatment factors to see how the TKI or other treatments affect the CVD risks in CML patients. We requested and used MIMIC Clinical Database as starting point and then accessed to real-world patient data from Radbound UMC+.

Please read the CML_CVD_data_request_info.pdf for data use and request details.

Please note that using patient data from MIMIC requires granted permission from https://physionet.org/content/mimiciii/1.4/